Navigation Links
Ocular Therapeutix, Inc. Receives IDE Approval to Conduct a Pivotal Clinical Trial for ReSure™ Sealant
Date:2/6/2012

BEDFORD, Mass., Feb. 6, 2012 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today that it has received IDE approval from the U.S. Food and Drug Administration to conduct a pivotal clinical trial with ReSure Sealant, a proprietary synthetic hydrogel polymer for ophthalmic use over clear corneal incisions.

The randomized, parallel-arm clinical trial will test the safety and efficacy of the device, relative to sutured closure, for prevention of postoperative fluid egress on clear corneal incisions following cataract or intraocular lens placement surgery.  The trial will be conducted at up to 24 sites throughout the United States. 

Cataract surgery is the most commonly performed surgery in the United States, with well over 3 million procedures conducted annually.  Clear corneal wound leaks are widely thought to be a contributing factor to many post-surgical complications.  Presently, ophthalmologists use stromal hydration to close these wounds, however, recent literature has shown that this technique may not be enough to create a watertight seal, and therefore more protection is necessary.  "In a time where wound integrity is under scrutiny, this product fills a void where our only option for closure of vulnerable incisions was sutures," stated Steven Dell, Medical Director of Dell Laser Consultants.  "ReSure Sealant could be a huge step forward for protecting our patients' eyes post-operatively."

"We are very excited to have developed a robust study with FDA's input to definitively demonstrate the utility of the ReSure Sealant compared to older methods of incision closure and management in clear corneal cataract surgery," stated Amar Sawhney, President and CEO of Ocular Therapeutix, Inc.  "We look forward to completing the trial and making the ReSure Sealant available to US physicians by next year."   

About Ocular Therapeutix, Inc.:

Founded in November 2006, Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. Ocular Therapeutix is also using its hydrogel technology for development of sustained ocular drug delivery vehicles, such as absorbable punctum plugs to deliver moxifloxacin for the treatment of bacterial conjunctivitis, and travoprost for the treatment of glaucoma.

About ReSure Sealant:

ReSure Sealant is a synthetic hydrogel polymer which is applied as a liquid and gels in situ on the ocular surface, creating a soft and lubricious surface barrier.  The Sealant is designed to stay on the incision in the immediate post-operative period when wounds are most vulnerable, after which it gently sloughs off in the patient's tears. 

 


'/>"/>
SOURCE Ocular Therapeutix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use
2. NeurOptics Introduces First Hand-held Variable Light Condition Pupillometer to Optimize Outcomes for Refractive Surgery and Premium Intraocular Lens Candidates
3. Oxford BioMedica Announces Ocular Programme Update
4. Reportlinker Adds Global Intraocular Lenses Industry
5. Ocular Therapeutix, Inc. Completes Series D Financing to Support Phase II Sustained Drug Delivery Clinical Trials
6. Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
7. Sylentis Completes Phase I Trial with SYL040012 to Treat Elevated Intraocular Pressure and Glaucoma
8. Tekia Enters Into Distribution Agreement With Fritz Ruck/T-MED, Germany to Market Its Accommodative Intraocular Lens to Treat Presbyopia
9. Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes
10. Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
11. Ocular Therapeutix, Inc. Appoints Two New Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016  Nearly 30 million people in ... the epidemic of diabetes. 1 However, nearly 40% ... glucose levels (hyperglycemia) and significant glucose variability. 2 These ... including cardiovascular events. If left untreated, hyperglycemia can lead ... disease or blindness. 3 As part ...
(Date:12/6/2016)... , Dec. 6, 2016 With opioids commonly used for ... the prescription drug market that has led to nationwide fatalities. ... to eight times stronger than heroin or morphine, resulting in likelihood ... , ... , vice president, clinical operations, Behavioral Health for HMC HealthWorks, explained ...
(Date:12/6/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... for patients with genomically defined diseases, today announced that ... million in shares of its common stock. In addition, ... option to purchase up to an additional of $18,750,000 ... with the public offering. All shares of common stock ...
Breaking Medicine Technology:
(Date:12/6/2016)... BROOK, Ill. (PRWEB) , ... December 06, 2016 ... ... disruptions in their brain networks that can be seen on a type of ... disease (PD) is a progressive disorder of the central nervous system characterized by ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum disease are ... serious health problems, such as cardiovascular illness, according to research cited in a ... Periodontics & Dental Implant Center notes that the correlation between periodontal disease and ...
(Date:12/6/2016)... ... ... According to a November 1 article published on Bustle, there ... drinking enough water, which can cause bad breath (known medically as halitosis). Dr. Farzad ... not only helps reduce the possibility of bad breath, but it can provide individuals ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... named Ajdin Camaga as a vice president of sales. , “Ajdin understands that ... “He works hard to understand what each client needs, and is persistent in ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
Breaking Medicine News(10 mins):